Biotechnology company 4basebio PLC (AIM: 4BB) on Wednesday announced the provision of its HQ synthetic DNA to a Tier 1 Pharma Company for late preclinical studies in an mRNA vaccine program. Following a successful opDNA evaluation study, the client has progressed to HQ opDNA. GMP grade material supply for clinical trials is expected in Q3.
Based in Cambridge, UK, 4basebio specialises in synthetic DNA products and non-viral, cell-targeting nucleic acid delivery platforms.
With a focus on advancing therapy medicinal products (ATMPs), the company aims to lead the market in manufacturing and supplying high-quality synthetic DNA products for research, therapeutic and pharmacological applications.
Additionally, the company develops target-specific non-viral vectors for efficient payload delivery in patients, including GMP-compliant DNA starting materials suitable for AAV viral vector production, mRNA vaccine and therapeutics production.
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Bavarian Nordic secures additional USD156.8m US government contract